FRM
Fox Run Management’s BioCryst Pharmaceuticals BCRX Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $159K | Sell |
17,725
-11,700
| -40% | -$105K | 0.03% | 773 |
|
|
2025
Q1 | $221K | Sell |
29,425
-38,615
| -57% | -$290K | 0.03% | 770 |
|
|
2024
Q4 | $512K | Buy |
68,040
+27,406
| +67% | +$206K | 0.09% | 434 |
|
|
2024
Q3 | $309K | Buy |
40,634
+4,522
| +13% | +$34.4K | 0.07% | 528 |
|
|
2024
Q2 | $223K | Buy |
36,112
+17,594
| +95% | +$109K | 0.04% | 636 |
|
|
2024
Q1 | $94.1K | Sell |
18,518
-523
| -3% | -$2.66K | 0.02% | 708 |
|
|
2023
Q4 | $114K | Sell |
19,041
-6,435
| -25% | -$38.5K | 0.03% | 675 |
|
|
2023
Q3 | $180K | Buy |
+25,476
| New | +$180K | 0.05% | 580 |
|
|
2022
Q4 | – | Sell |
-19,854
| Closed | -$250K | – | 625 |
|
|
2022
Q3 | $250K | Buy |
19,854
+4,989
| +34% | +$62.8K | 0.1% | 410 |
|
|
2022
Q2 | $157K | Buy |
+14,865
| New | +$157K | 0.08% | 438 |
|
|
2017
Q4 | – | Sell |
-23,400
| Closed | -$123K | – | 671 |
|
|
2017
Q3 | $123K | Buy |
23,400
+700
| +3% | +$3.68K | 0.03% | 639 |
|
|
2017
Q2 | $126K | Buy |
+22,700
| New | +$126K | 0.04% | 587 |
|